Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors

International Journal of Cancer

Volumn 102, Issue 1, 2002, Pages 86-90

  Karamouzis, Michalis V ^a   Likaki Karatza, Eleni ^a   Ravazoula, Panagiota ^a   Badra, Filitsa A ^a   Koukouras, Dimitrios ^a   Tzorakoleftherakis, Evagelos ^a   Papavassiliou, Athanasios G ^a   Kalofonos, Haralambos P ^a,b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Apoptosis; C erbB 2; Cell proliferation; Estrogen receptor; Microcalcification; Non palpable breast carcinoma; Progesterone receptor

Indexed keywords

BIOLOGICAL MARKER; DNA FRAGMENTATION FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FAS ANTIGEN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CALCIFICATION; BREAST CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0036837247     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10654     Document Type: Article

References (43)

1. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: Mammograms and physical examination. J Clin Oncol 2001;19:3490-9.
2. Miettinen OS, Henschke CI, Pasmantier MW, Smith JP, Libby DM, Yankelevitz DF. Mammographic screening: no reliable supporting evidence? Lancet 2002;359:404-6.
3. Fondrinier E, Lorimier G, Guerin-Boblet V, Bertrand AF, Mayras C, Dauver N. Breast microcalcifications: multivariate analysis of radiologic and clinical factors for carcinoma. World J Surg 2002;26: 290-6.
4. Zaugg K, Bodis S. Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast? Radiother Oncol 2000;55:95-9.
5. Idvall I, Andersson C, Fallenius G, Inbvar C, Ringberg A, Strand C, Akerman M, Ferno M. Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening. Acta Oncol 2001;40:653-9.
6. Mesurolle B, Ariche-Cohen M, Mignon F, Goumot PA. Clustering of breast microcalcifications on digital mammography: which parameters? Clin Radiol 2002;57: 75.
7. Dinkel H-P, Gassel AM, Tschammler A. Is the appearance of micro-calcifications on mammography useful in predicting histological grade of malignancy in ductal carcinoma in situ? Br J Radiol 2000; 73:938-44.
8. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
9. Mollino A, Pavarana M, Micciolo R, Nortilli R, Pedersini R, Manno P, Bozzi P, Bonetti F, Piubello Q, Cetto GL. Comparative study of clinical, pathological and biological characteristics of symptomatic versus asymptomatic breast cancers. Ann Oncol 2000; 11: 581-6.
10. Orel SC, Kay N, Reynolds C, Sullivan DC. BI-RADS categorization as a predictor of malignancy. Radiology 1999;211:845-50.
11. de Paredes ES, Langer TG, Cousins J. Interventional breast procedures. Curr Probl Diagn Radiol 1998;27:133-84.
12. Diaz-Cano SJ, Garcia-Molliner M, Carney W, Wolfe HJ. Bcl-2 expression and DNA fragmentation in breast carcinoma, pathologic and steroid hormone receptors correlates. Diagn Mol Pathol 1997;6:199-208.
13. Perin T, Canzonieri V, Massarut S, Bidoli E, Rossi C, Roncadin M, Carbone A. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur J Cancer 1996;32A: 1148-55.
14. Rehman S, Crow J, Revell PA. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Pathol Oncol Res 2000;6:256-63.
15. Yakirevich E, Maroun L, Cohen O, Izhak OG, Rennert G, Resnick MB. Apoptosis, proliferation, and Fas (APO, CD95)/Fas ligand expression in medullary carcinoma of the breast. J Pathol 2000;192: 166-73.
16. Crisi GM, Ricci A Jr. Microcalcifications in the breast and the pathologist. Am J Surg Pathol 2002;26:676-7.
17. Ferranti C, Coopmans de Yoldi G, Biganzoli E, Bergonzi S, Mariani L, Scaperrotta G, Marchesini M. Relationships between age, mammographic features and pathological tumor characteristics in non-palpable breast cancer. Br J Radiol 2000;73:698-705.
18. Walker RA, Dearing SJ, Brown LA. Comparison of pathological and biological features of symptomatic and mammographically detected ductal carcinoma in situ of the breast. Hum Pathol 1999;30:943-8.
19. Alexander FE, Anderson TJ, Hubbard AL. Screening status in relation to biological and chronological characteristics of breast cancers: a cross sectional survey. J Med Screen 1997;4:152-7.
20. Moezzi M, Melamed J, Vamvakas E, Inghirami G, Mitnick J, Quish A, Bose S, Zelman G, Roses D, Harris M, Feiner H. Morphological and biological characteristics of mammogram -detected invasive breast cancer. Hum Pathol 1996;27:944-8.
21. Tweedie E, Tonkin K, Kerkvliet N, Doig GS, Sparrow RK, O'Malley FP. Biologic characteristics of breast cancer detected by mammography and by palpation in a screening program: A pilot study. Clin Invest Med 1997;20:300-7.
22. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999; 187:272- 8.
23. Heimann R, Hellman S. Aging, progression, and phenotype in breast cancer. J Clin Oncol 1998;16:2686-92.
24. Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst 1997;22:151-6.
25. Zheng WQ, Lu J, Zheng JM, Hu FX, Ni CR. Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression. Steroids 2001;12:905-10.
26. Cowan WK, Kelly P, Sawan A, Cunliffe WJ, Henry L, Higgs MJ, Lunt LG, Young JR, Home CH, Angus B. The pathological and biological nature of screen-detected breast carcinomas: A morphological and immunohistochemical study. J Pathol 1997;182:29-35.
27. Duffy MJ. Biochemical markers in breast cancer. Which ones are clinically useful? Clin Biochem 2001;34:347-52.
28. Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ 3rd, Liu ET, Conway K. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000;18:267-74.
29. Eppenberger-Castori S, Kueng W, Benz C, Caduff R, Varga Z, Bannwart F, Fink D, Dieterich H, Hohl M, Muller H, Paris K, Schoumacher F, et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645-56.
30. Fiche M, Aret-Loiseau H, Heymann MF, Moussaly F, Digabel C, Joubert M, Classe JM, Dravet F, Fumoleau P, Ross J, Maugard CM. Genetic alterations in early-onset invasive breast carcinomas: correlation with c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype. Int J Cancer 1999;84:511-5.
31. Ross JS, Fletcher JA. HER-2/neu (c-erbB-2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112:S53-S67.
32. Chung YL, Sheu ML, Yang SC,. Lin CH, Yen SV. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between HER-2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002;97:306-12.
33. Wang SC, Zhang L, Hortobagyi GN, Hung MC. Targeting HER-2: recent developments and future directions for breast cancer patients. Semin Oncol 2001;28:21-9.
34. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17:2941-53.
35. Yang QF, Sakurai T, Yoshimura G, Shan L, Suzuma T, Tamaki T, Umemura T, Kokawa Y, Nakamura M, Tang W, Utsunomiya H, et al. Expression of bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res Treat 2000;61:211-6.
36. Bozzetti C, Nizzoli R, Naldi N, Guazzi A, Camisa R, Bella MA, Cocconi G. Bcl-2 expression of fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors. Cancer 1999;87:224-30.
37. Gee JM, Robertson JF, Ellis IO, Wilsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI. Immunocyto-chemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994;59:619-28.
38. Liang Y, Nulander KD, Yan C, Schor NF. Role of caspase 3-dependent Bcl-2 cleavage in potentiation of apoptosis by Bcl-2. Mol Pharmacol 2002;61:142-9.
39. Veronese S, Mauri FA, Caffo O, Scaioli M, Aldovini D, Perrone G, Galligioni E, Doglioni C, Dalla Palma P, Barbareschi M. Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int J Cancer 1998;79:13-8.
40. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998;391: 96-9.
41. Li LY. Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001; 412:95-9.
42. Reiner T, Hermring C, Koczan D, Richter D, Gerber B, Kabelitz D, Friese K, Thiesen HJ. FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res 2000;60:822-8.
43. Muschen M, Re D, Betz B, Moers C, Wolf J, Niederacher D, Diehl V, Beckmann MW. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene. Int J Cancer 2001;92:309-10.